Cork

CORK, Ireland, August 26, 2011 - Alimentary Health Limited (AH), the specialty biotechnology company, today announces that it has entered into a development partnership with Norgine, a leading European specialty pharmaceutical company with a strong portfolio of internal development projects, principally in the areas of gastroenterology, hepatology and supportive care.

CORK, Ireland, January 27, 2011 - Tibotec Pharmaceuticals today announced that it has granted multiple non-exclusive licenses to generic manufacturers including Hetero Drugs Limited, Matrix Laboratories Limited (a Mylan company) of India and Aspen Pharmacare of South Africa to manufacture, market and distribute the investigational non-nucleoside reverse transcriptase inhibitor rilpivirine hydrochloride (TMC278), pending its approval for use with other antiretroviral agents in the treatment of treatment-naive HIV-1 infected adults.

CORK, Ireland, September 3, 2010 - Tibotec Pharmaceuticals today announced its submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TMC278 (rilpivirine, as hydrochloride), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV.

CORK, Ireland - Marketed as Align(R) by Procter & Gamble Alimentary Health Ltd.